Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M

Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder. The Carlsbad company develops RNA-targeted therapies for neurology, cardiology and other rare conditions. The Ionis drug, sapablursen, is an RNA-targeted therapy for a rare blood disease called polycythemia vera. The condition causes the overproduction of red blood cells, thickening the …

Belgian biotech firm Augustine Therapeutics raises €78 million in funding round

Leuven-based biotech company Augustine Therapeutics has raised €77.7 million in a new funding round. Among the investors is Novo Holdings, the...

Augustine secures $85m to advance Charcot-Marie-Tooth candidate - Pharmaceutical Technology

Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a Phase I/II trial in Charcot-Marie-Tooth (CMT) disease.

Augustine decloaks with $85m for nerve disease programme

Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.

Leuven-based Augustine Therapeutics raises €77.7M to advance neuromuscular drug development - Silicon Canals

Leuven, Belgium-based Augustine Therapeutics NV, a biotechnology company, has secured €77.7M in an oversubscribed Series A funding round co-led by Novo Holdings and Jeito Capital. Existing investors, including Asabys Partners, Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital, participated in the round. The company will use the fun…

Leuven-based Augustine Therapeutics raises 78 million euros in one of the largest capital rounds ever in Belgian biotech. After pharmaceutical giant Eli Lilly, Novo Holdings, the holding company above Ozempic maker Novo Nordisk, is now also putting money on the table.